Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Servier Affaires Médicales
The objectives on patients still alive one year after the first cycle of nal-IRI :
* Characterize mPDAC patient population according to their demographics
* Identify PDAC treatment by line of treatment from diagnosis to last treatment
* Explore prognostic factors of longer Overall Survival (OS) and Progression Free Survivor (PFS) among mPDAC patients showing long-term Survival
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years (≥ 19 years in South Korea)
Cytologically confirmed mPDAC at initiation of the nal-IRI treatment
All patients receiving a nal-IRI + 5-flurouracil/leucovorin regimen should have been pre-treated with a gemcitabine-based regimen
Initiation of a systemic therapy with nal-IRI (index date) during the study eligibility period (between January 1, 2018, and December 31, 2021)
At least one cycle of nal-IRI-containing regimen should have been administered
A minimum 1-year survival from the index date (initiation date of nal-IRI-containing regimen)
Availability of data related to survival outcomes in the patient medical record
Patients deceased or not at the time of enrollment will be eligible for inclusion in the study
You may not be if
No documentation of systemic therapy outcomes or prior treatments in patient medical records
Patients with second concomitant metastatic malignancy
Clareo Health | RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
